Most guidance about GLP-1 providers assumes you are choosing your first one. In practice a large and growing number of patients are on their second or third — because prices rose, service deteriorated, a molecule became unavailable, or the provider itself changed what it sells.
That last category is no longer hypothetical. The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, Hims & Hers pivoted from compounded to brand-name medication under a Novo Nordisk agreement, and Novo Nordisk is discontinuing Saxenda in early 2027. Providers are changing what they can supply, sometimes with little notice.
The thing worth protecting through any of this is continuity. An unplanned gap in GLP-1 treatment is not merely inconvenient — it can mean losing tolerance built through titration, and restarting lower than where you were.
This article covers switching deliberately, switching under pressure, and the sequence that avoids a gap in either case.
The Rules of a Clean Switch
Never Cancel Before the New Supply Is Confirmed
The single most common mistake. Cancel your existing subscription only once the new provider has approved you, priced you, and ideally shipped. Overlap costs one month; a gap can cost you your titration position.
A Gap Can Mean Restarting Lower
Tolerance to GLP-1 side effects is built through gradual escalation. After a significant interruption, a clinician may restart you at a lower dose and re-titrate — which is both slower and less comfortable than continuing.
Know Your Exact Current Regimen
Molecule, dose in milligrams, injection day, formulation including any additives, and how long you have been at your current dose. A new provider will ask, and precision matters.
Confirm the New Provider Carries Your Molecule
Several providers offer only one. Switching for price and discovering your molecule is unavailable is a wasted intake and a delay you did not budget for.
Ask About Pharmacy and Formulation, Not Just Price
A cheaper provider using an unnamed pharmacy with a different additive profile is not straightforwardly cheaper. Our guide to what is in compounded vials covers why formulation differences matter.
Get Cancellation Terms Before You Need Them
Prepaid and multi-month plans are common, and terms are frequently unpublished. Knowing your exit before you enter is the difference between switching freely and being locked in.
The Sequence That Avoids a Gap
Order matters more than anything else here. Follow this and a switch costs you at most one overlapping month.
1. Document Your Current Regimen
Write down the molecule, your exact dose in milligrams, your injection day, the formulation including any additives such as B12 or glycine, how long you have been at this dose, and your current supply remaining. This is what a new provider needs.
2. Complete the New Provider Intake While Still Supplied
Do this with at least three to four weeks of medication in hand. Intake, clinical review, approval and shipping all take time, and the process is far less stressful when you are not counting down.
3. Confirm Dose Continuation Explicitly
Ask the new provider whether they will continue you at your current dose or restart lower. Do not assume — some will continue, some re-titrate, and it materially affects the experience.
4. Confirm the All-In Price at Your Actual Dose
Not the advertised entry price. Ask what you will pay at the dose you are on, including any membership or shipping charge, so the comparison against your current provider is real.
5. Receive and Inspect the First Shipment
Only after medication is in your refrigerator, cold pack intact and formulation as expected, is the switch actually complete. Injectables are temperature-sensitive — verify before relying on it.
6. Then Cancel the Old Subscription
Now, and in writing. Keep the confirmation. If you prepaid, follow up specifically on any refund due for unused months.
Switching Under Pressure
Sometimes the decision is not yours. A provider stops carrying your molecule, changes formulation, raises prices sharply, or exits the compounded market entirely. The sequence above still applies — you simply have less time.
If you have been given notice, use it immediately rather than waiting to see whether the situation resolves. Providers rarely reverse these decisions, and every week of delay is a week less buffer.
If your provider is moving from compounded to brand-name medication, as Hims did under its Novo Nordisk agreement, that is not automatically bad news. Approved medication carries full FDA review, which compounded does not. But confirm the specific product, dose and price before accepting a transition — brand-name pricing works differently.
If you are affected by the Saxenda discontinuation, that has its own timeline and its own options, covered in our discontinuation guide.
And if the compounded regulatory position narrows further, the alternatives are better than most patients assume. Brand-name access improved considerably in 2026, and Medicare beneficiaries may have a $50 route through the Bridge programme.
Do Not Stockpile as a Strategy
It is tempting and it is not a plan. Injectables have beyond-use dates and storage requirements, and prescriptions are written for defined quantities. Use the time to arrange a proper transition instead.
Do Not Buy From Unverified Sources
The single worst response to a supply disruption is sourcing medication outside a legitimate prescribing relationship. The FDA has warned about unapproved GLP-1 products and about dosing errors with compounded preparations. A gap is recoverable; an unsafe product may not be.
Re-Check Insurance Whenever Anything Changes
Coverage shifts, and the calculation has moved considerably in 2026. If you are being forced to switch anyway, that is exactly the right moment to check whether an insurance route now beats cash-pay.
What to Ask a Prospective Provider
The same questions apply whether you are switching by choice or necessity. These are the ones that actually differentiate providers.
| Question | Why It Matters |
|---|---|
| Do you carry my molecule at my dose? | Several providers are single-molecule. Establish this before completing an intake. |
| Will you continue my current dose or restart me lower? | Materially affects comfort and progress. Some continue; some re-titrate. |
| What is my all-in monthly cost at my actual dose? | Entry prices frequently do not apply at maintenance doses. |
| Which pharmacy dispenses, and is it 503A or 503B? | Sourcing transparency varies enormously. Some providers name pharmacies; most do not. |
| What exactly is in the formulation, at what doses? | Additives differ between providers. A switch can change what you are injecting. |
| What are the cancellation and refund terms? | Ask before enrolling, not when you want to leave. Frequently unpublished. |
| How do I reach a clinician, and how fast? | Matters most during titration — which a switch may put you back into. |
| Is shipping included and temperature-controlled? | A separate shipping charge changes the comparison; cold chain affects the product. |
Our Take
Overlap, never gap. If you take one thing from this article: complete the new provider’s intake, get approved, get priced, and get medication in hand before cancelling anything. Paying for one overlapping month is a small price against losing your titration position and re-experiencing dose escalation.
Switch on the full picture, not the headline price. A cheaper provider using an unnamed pharmacy with a different additive profile and no published cancellation terms may not be cheaper in any sense that matters. Our pricing models guide covers how to compare properly, and what is in your vial covers the formulation side.
If you are switching under pressure, act on the notice immediately. Providers rarely reverse supply decisions, and the patients who struggle are the ones who waited. Use the buffer you have rather than the buffer you wish you had.
And treat any forced switch as a prompt to re-check everything. Insurance coverage, the Medicare Bridge if you are eligible, and brand-name self-pay pricing have all moved in patients’ favour during 2026. The route that was best for you a year ago may not be the best one now.
Frequently Asked Questions
Can I switch GLP-1 providers without stopping treatment?
Yes, if you sequence it correctly. Complete the new provider’s intake, get approved and priced, and receive your first shipment before cancelling the old subscription. That may mean paying for one overlapping month, which is a small cost against an interrupted course of treatment.
What happens if I have a gap in treatment?
Tolerance to GLP-1 side effects is built through gradual dose escalation. After a significant interruption, a clinician may restart you at a lower dose and re-titrate, which is slower and less comfortable than continuing uninterrupted. The length of gap that matters is a clinical question — ask your prescriber.
Will a new provider continue my current dose?
Some will, some will re-titrate from a lower dose. It depends on the provider and the clinician’s assessment. Ask explicitly before completing an intake rather than assuming, because it materially affects your experience over the following weeks.
What information do I need to switch?
Your molecule, exact dose in milligrams, injection day, the formulation including any additives such as B12 or glycine, how long you have been at your current dose, and your remaining supply. Precision helps the new clinician make a sensible decision about continuation.
What if my provider stops carrying my medication?
Act on the notice immediately rather than waiting to see whether it resolves — providers rarely reverse these decisions. Use the sequence above with whatever buffer you have, and treat it as a prompt to re-check insurance and brand-name options, both of which improved during 2026.
Should I stockpile medication before switching?
No. Injectables have beyond-use dates and storage requirements, and prescriptions are written for defined quantities. Stockpiling is not a substitute for arranging a proper transition, and it introduces its own risks around storage and expiry.
What if my provider switches me from compounded to brand-name?
That is not automatically bad news — approved medication carries full FDA review of safety, efficacy and manufacturing quality, which compounded preparations do not. But confirm the specific product, dose and price before accepting the transition, because brand-name pricing works differently and may be higher or lower depending on your situation.
Is it worth switching just to save money?
Only after comparing the full picture. Add every recurring cost at your actual maintenance dose, then ask about pharmacy sourcing, formulation contents and cancellation terms. A cheaper headline price attached to an unnamed pharmacy and unpublished terms is not reliably cheaper in any meaningful sense.
Disclosure:
This article is based on publicly available information including FDA communications on compounded GLP-1 products and dosing errors, the FDA’s April 2026 proposal regarding the 503B bulks list, Novo Nordisk’s announced discontinuation of Saxenda, public reporting on the March 2026 Novo Nordisk and Hims & Hers agreement, and provider-published policies, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Nothing here is medical advice — decisions about dose continuation, titration and treatment interruption belong entirely to a clinician who knows your history. Never source prescription medication outside a legitimate prescribing relationship. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Switching Between GLP-1 Medications
Changing molecule rather than provider, and how dosing is handled.
How to Vet a GLP-1 Provider
Red flags, green flags and the questions to ask before you pay.
The FDA 503B Bulks List Proposal
Why provider supply may change, and what it means for continuity.
The Five GLP-1 Pricing Models
How to compare a prospective provider against your current one properly.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →